Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7548322 | 0.82 | GAA (0.44) | MTNR1AMTNR1BL3MBTL1TSHRGLS | |
| SCHEMBL8649137 | 0.81 | MTNR1A (0.42) | MTNR1AMTNR1BL3MBTL1TSHRGLS | |
| SCHEMBL31142951 | 0.81 | ALDH1A1 (0.48) | L3MBTL1TSHRGLSNAMPTCA1 | |
| SCHEMBL5209897 | 0.81 | L3MBTL1 (0.52) | L3MBTL1NAMPTCA1CA2SMN1; SMN2 | |
| SCHEMBL15862359 | 0.81 | GAA (0.43) | MTNR1AMTNR1BL3MBTL1GLSNAMPT | |
| SCHEMBL6185932 | 0.81 | ALDH1A1 (0.51) | L3MBTL1HDAC6SMN1; SMN2HDAC1 | |
| SCHEMBL2037435 | 0.81 | CYP1A2 (0.43) | L3MBTL1TSHRSMN1; SMN2GAA | |
| SCHEMBL1985433 | 0.80 | HDAC1 (0.51) | L3MBTL1TSHRGLSNAMPTCA1 | |
| SCHEMBL30558282 | 0.80 | MTNR1A (0.45) | MTNR1AMTNR1BL3MBTL1CA1HDAC6 | |
| SCHEMBL14354579 | 0.79 | ALDH1A1 (0.53) | L3MBTL1TSHRHDAC6SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MTNR1A 3862/4885MTNR1B 4336/4885L3MBTL1 3015/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | MTNR1A 3847/4885MTNR1B 4325/4885L3MBTL1 3016/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MTNR1A 3862/4885MTNR1B 4336/4885L3MBTL1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.